Loading…
Xtant Medical Holdings, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in XTNT.
▼ -67.3% over 5Y.
today you would have $338.47▼ -66.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.78 | $0.44 | $1.13 | $0.66 | $0.56 | $1.20 | $1.60 | $1.61 | $6.84 | $6.60 | $33.60 | $36.36 | $60.00 | $150.00 | $343.20 | $1,020.00 | |
| P/E | — |
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 13.3x operating profit, less net debt. Sees the business before its financing, so debt does not distort the comparison. Banks have no EBITDA — interest is their revenue, not a cost.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SCYXScynexis Inc | $5.39 | — | 0.8x | — | -18.38% | $53.63M |
| NTRBNutriBand Inc. | $4.46 | — | 9.0x | — | -145.72% | $54.22M |
| COCHEnvoy Medical, Inc. | $0.69 | — | 14.4x | — | — | $53.27M |
| BTMDbiote Corp. | $1.57 | 11.2x |
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.
Company description provided by Yahoo Finance.
| 26.0x |
| — |
| 113.0x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| P/S | 0.9x | 0.8x | 0.5x | 1.6x | 1.2x | 0.9x | 1.8x | 0.3x | 0.3x | 1.1x | 0.1x | 0.6x | 0.6x | 0.8x | 1.6x | 4.0x | 20.4x |
| P/B | 2.9x | 2.1x | 1.4x | 2.9x | 2.1x | 1.6x | 6.4x | — | — | — | — | 3.8x | — | — | 12.6x | 21.9x | — |
| EPS | $0.03 | -$0.12 | $0.01 | -$0.09 | -$0.06 | -$0.25 | -$0.63 | -$5.97 | -$34.76 | -$18.46 | -$2.88 | -$21.12 | -$33.60 | -$21.60 | -$9.60 | -$73.20 |
| Profit margin | -14.33% | 3.71% | -14.03% | 0.72% | -14.64% | -8.77% | -13.17% | -12.71% | -97.09% | -63.44% | -21.66% | -3.66% | -29.74% | -38.38% | -23.39% | -9.97% | -126.27% |
| ROE | -24.83% | 9.76% | -38.29% | 1.29% | -24.83% | -15.70% | -48.39% | — | — | — | — | -24.50% | — | — | -182.26% | -54.65% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Not the average of the seven numbers above. Four of the seven start from the same earnings per share — Graham, Lynch, sector multiples and its own history — so averaging all seven would let one input count four times and drown out the others. Instead each family produces one number, and the fair price is the average of the families that answered. A family with two working formulas contributes their average, not two votes.
2 methods answered, across 2 families.
Every formula reads the same reported statements and they can be wrong together. The margin is room for that.
+389.0% from the average.
These are models, not forecasts, and not investment advice. Change one assumption and the number changes with it — that is a property of valuation, not a defect of this page.
| — |
| — |
| — |
| $53.22M |
| HRTXHeron Therapeutics Inc | $0.29 | — | 9.4x | — | — | $55.25M |
| ELOXEloxx Pharmaceuticals, Inc. | $15.07 | 4.7x | 1.3x | — | — | $51.79M |